Price Target Update on Baxter International (NYSE:BAX)

Baxter International (NYSE:BAX) : The consensus price target for Baxter International (NYSE:BAX) is $48.83 for the short term with a standard deviation of $5.49. The most optimist securities analyst among the 6 who monitor the stock believes that the stock can reach $60, however, the pessimist price target for the company is $46.

Other Equity analysts have also commented on the company shares. Evercore ISI Group initiates coverage on Baxter International (NYSE:BAX) . Analysts at the Evercore ISI Group have a current rating of Buy on the shares. The rating by the firm was issued on May 4, 2016.

Baxter International (NYSE:BAX): stock turned positive on Thursday. Though the stock opened at $45.18, the bulls momentum made the stock top out at $45.96 level for the day. The stock recorded a low of $45.16 and closed the trading day at $45.96, in the green by 2.27%. The total traded volume for the day was 3,274,706. The stock had closed at $44.94 in the previous days trading.

The company shares have rallied 14.37% from its 1 Year high price. On May 12, 2016, the shares registered one year high at $46.95 and the one year low was seen on Oct 6, 2015. The 50-Day Moving Average price is $44.39 and the 200 Day Moving Average price is recorded at $40.45. On the companys insider trading activities, Almeida Jose E, CEO of Baxter International Inc, had purchased 11,691 shares on May 23, 2016. The total value of the transaction was $499,790. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.